Status:
COMPLETED
Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Restless Legs Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
The objectives of the Post Market Surveillance (PMS) study are to evaluate the treatment effect of pramipexole on Restless Legs Syndrome (RLS) severity as measured by International Restless Legs Ratin...
Eligibility Criteria
Inclusion
- Primary Restless Legs Syndrome (i.e. idiopathic RLS)
- Indication for treatment with pramipexole
- Male or female patients older than 18 years
Exclusion
- Any contraindications according to the Summary of Product Characteristics (SPC): hypersensitivity to pramipexole or to any of the excipients
- Current treatment with pramipexole
Key Trial Info
Start Date :
September 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
549 Patients enrolled
Trial Details
Trial ID
NCT00721279
Start Date
September 1 2007
Last Update
June 4 2014
Active Locations (127)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site
Absam, Austria
2
Boehringer Ingelheim Investigational Site
Absdorf, Austria
3
Boehringer Ingelheim Investigational Site
Afritz, Austria
4
Boehringer Ingelheim Investigational Site
Alkoven, Austria